Monday Morning Recap: The Week in Drug & Device Law & Policy

Filed in Monday Morning Recap by on December 16, 2013 0 Comments

Picture3What follows is a weekly feature here at Health Reform Watch.  Each Monday morning, we provide a recap of the drug and device law and policy developments over the previous week that caught our eye and made us think.  Credit for the format goes to Seton Hall Law alum Jordan T. Cohen, who used it to great effect in his series of Reform Rodeo posts.

1. At The New Yorker, Ian Parker tells a gripping story about the development and approval of a next generation insomnia drug.  Parker ends the article with the following question:  “How successfully can a pharmaceutical giant—through advertising and sales visits to doctors’ offices—sell a drug at a dose that has been repeatedly described as ineffective by the scientists who developed it?”

2. An article by Ariana Eunjung Cha in The Washington Post suggests that fears of risk classification by design in the new health insurance exchanges may be coming true.  Cha writes: “The nation’s new health-care law says insurers can’t turn anyone away, even people who are sick. But some companies, patient advocates say, have found a way to discourage the chronically ill from enrolling in their plans: offer drug coverage too skimpy for those with expensive conditions.”

3. At Fierce Pharma, Tracy Staton reports on a fine issued by the Swedish stock exchange against a drug company, Medivir, that failed to respond for three hours to a conversation on Twitter that sent the company’s shares soaring.

4. Also in the news last week was the FDA’s decision to “implement[] a voluntary plan with industry to phase out the use of certain antibiotics for enhanced food production. … Because all uses of antimicrobial drugs, in both humans and animals, contribute to the development of antimicrobial resistance, it is important to use these drugs only when medically necessary.”

5. Finally, at The Incidental Economist Aaron Carroll highlights a study in JAMA Pediatrics that found that the “vast, vast majority of drugs used in the care of neonates have not been studied in neonates.”  Carroll writes: “We need to work on fixing this. Legislation hasn’t done enough.”

Tags: , , , , ,

About the Author ()

Leave a Reply

Your email address will not be published. Required fields are marked *